Skip to main content
. 2014 Dec 3;32(2):305–312. doi: 10.1007/s10815-014-0392-z

Table 1.

Characteristics of breast cancer patients who desired to undergo ovarian tissue cryopreservation

No. Age (years old) Marital Status Past pregnancies BMI Phase of mentruation (Day) AMH (ng/ml) No. of oocytes No. of ovarian tissues Procedure of laparoscopy Molecular subtype Pretreatment
1 34 Single None 23.7 F (6) 4.2 17 18 Multiple A
2 33 Married None 25 L (22) 6.90 11 12 Multiple B FEC*4 DOC/HCN*4
3 32 Single None 19 F (6) 3.16 12 28 Multiple B
4 39 Single None 20.8 F (3) 3.98 5 16 Multiple A Radiation
5 39 Married None 19.2 F (4) 1.57 4 18 Multiple B
6 29 Married None 23.1 F (3) 5.82 19 26 Multiple B
7 33 Married 1G1P 30.6 F (7) 3.06 2 16 Multiple B
8 30 Single None 23.8 L (22) 6.62 7 15 Multiple B
9 36 Single None 201 F (6) 1.37 7 17 Multiple B GnRHa 2y, TAM 5y
10 41 Married 1G0P 32.8 L (17) 0.72 4 9 Multiple B
11 36 Single 1G0P 18.2 unknown 1.45 5 20 Multiple B
12 35 Single None 19.4 F (7) 0.87 0 22 Multiple B
13 33 Single None 19.7 L (28) 6.13 26 23 Multiple B
14 33 Single None 19.9 L (25) 2.05 9 18 Multiple A
15 34 Married None 18.9 F (9) 1.09 0 20 Multiple B CE*4 DOC/HCN*4
16 32 Single None 19.5 F (8) 4.35 14 17 Multiple HER2
17 34 Single None 20.1 L (16) 2.21 6 12 Single Tri neg
18 37 Married None 17.7 L (25) 0.7 2 15 Single A TAM 2 M
19 36 Married 1G0P 23.9 L (32) 3.03 10 6 Single B
20 29 Single None 19.6 unknown 5.2 6 19 Single B
21 33 Married 3G0P 20.2 F (14) 5.31 9 17 Single B surgery
22 38 Married 1G0P 24.5 F (8) 0.52 10 8 Single B
23 34 Single None 21.1 F (13) 3.56 2 11 Single A
24 36 Single None 22.3 L (23) 3.82 5 14 Single B
25 34 Single None 18.6 F (3) 5.51 9 14 Single B
26 25 Single None 17.6 F (6) 7.73 17 14 Single B
27 25 Single 1G0P 19 L (29) 2.54 8 16 Single B

F Follicular phase, L Luteal phase, Multiple multiple port surgery, Single Single port laparoscopy, A Luminal A type, B Luminal B type, Tri neg triple negative type, TAM tamoxifen, FEC 5-FU and epirubicin and cyclophosphamide, DOC docetaxel, HCN trastuzumab, CE cyclophosphamide and epirubicin, GnRHa gonadotropin releasing hormone agonist